[1]
Wakili, R.; Voigt, N.; Kääb, S.; Dobrev, D.; Nattel, S. Recent advances in the molecular pathophysiology of atrial fibrillation. J. Clin. Invest., 2011, 121(8), 2955-2968.
[2]
Dobrev, D.; Nattel, S. New antiarrhythmic drugs for treatment of atrial fibrillation. Lancet, 2010, 375(9721), 1212-1223.
[3]
Nattel, S.; Burstein, B.; Dobrev, D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythm Electrophysiol, 2008, 1(1), 62-73.
[4]
Frustaci, A.; Chimenti, C.; Bellocci, F.; Morgante, E.; Russo, M.A.; Maseri, A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation, 1997, 96(4), 1180-1184.
[5]
Haïssaguerre, M.; Jaïs, P.; Shah, D.C.; Takahashi, A.; Hocini, M.; Quiniou, G.; Garrigue, S.; Le Mouroux, A.; Le Métayer, P.; Clémenty, J. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N. Engl. J. Med., 1998, 339(10), 659-666.
[6]
de Vos, C.B.; Pisters, R.; Nieuwlaat, R.; Prins, M.H.; Tieleman, R.G.; Coelen, R.J.; van den Heijkant, A.C.; Allessie, M.A.; Crijns, H.J. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J. Am. Coll. Cardiol., 2010, 55(8), 725-731.
[7]
Wolf, P.A.; Abbott, R.D.; Kannel, W.B. Atrial fibrillation as an independent risk factor for stroke: The Framingham study. Stroke, 1991, 22(8), 983-988.
[8]
Kannel, W.B.; Wolf, P.A.; Benjamin, E.J.; Levy, D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am. J. Cardiol., 1998, 82(8A), 2N-9N.
[9]
Zhang, W.; Brombosz, S.M.; Mendoza, J.L.; Moore, J.S. A high-yield, one-step synthesis of o-phenylene ethynylene cyclic trimer via precipitation-driven alkyne metathesis. J. Org. Chem., 2005, 70(24), 10198-10201.
[10]
Odutayo, A.; Wong, C.X.; Hsiao, A.J.; Hopewell, S.; Altman, D.G.; Emdin, C.A. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. BMJ, 2016, 354, i4482.
[11]
Fang, M.C.; Singer, D.E.; Chang, Y.; Hylek, E.M.; Henault, L.E.; Jensvold, N.G.; Go, A.S. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: The AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation, 2005, 112(12), 1687-1691.
[12]
Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1066 patients from 3 clinical trials. Arch. Intern. Med., 1998, 158(12), 1316-1320.
[13]
Goldsmith, I.L.G.; Blann, A.D.; Kumar, P.; Carter, P.; Patel, R.L. Endocardial damage is common in the left atrial appendage of patients with mitral valve disease: implications for left atrial thrombogenesis. Eur. Heart J., 1999, 20, 192.
[14]
Feng, D.; D’Agostino, R.B.; Silbershatz, H.; Lipinska, I.; Massaro, J.; Levy, D.; Benjamin, E.J.; Wolf, P.A.; Tofler, G.H. Hemostatic state and atrial fibrillation (the Framingham Offspring Study). Am. J. Cardiol., 2001, 87(2), 168-171.
[15]
Gustafsson, C.; Blombäck, M.; Britton, M.; Hamsten, A.; Svensson, J. Coagulation factors and the increased risk of stroke in nonvalvular atrial fibrillation. Stroke, 1990, 21(1), 47-51.
[16]
Hughes, M.; Lip, G.Y. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb. Haemost., 2008, 99(2), 295-304.
[17]
Lip, G.Y.; Nieuwlaat, R.; Pisters, R.; Lane, D.A.; Crijns, H.J. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The euro heart survey on atrial fibrillation. Chest, 2010, 137(2), 263-272.
[18]
Benjamin, E.J.; Wolf, P.A.; D’Agostino, R.B.; Silbershatz, H.; Kannel, W.B.; Levy, D. Impact of atrial fibrillation on the risk of death: The Framingham heart study. Circulation, 1998, 98(10), 946-952.
[19]
Camm, A.J.; Kirchhof, P.; Lip, G.Y.; Schotten, U.; Savelieva, I.; Ernst, S.; Van Gelder, I.C.; Al-Attar, N.; Hindricks, G.; Prendergast, B.; Heidbuchel, H.; Alfieri, O.; Angelini, A.; Atar, D.; Colonna, P.; De Caterina, R.; De Sutter, J.; Goette, A.; Gorenek, B.; Heldal, M.; Hohloser, S.H.; Kolh, P.; Le Heuzey, J.Y.; Ponikowski, P.; Rutten, F.H.; Association, E.H.R.; Surgery, E.A.C-T.; Guidelines, E.C.P. Guidelines for the management of atrial fibrillation: The task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Europace, 2010, 12(10), 1360-1420.
[20]
Heeringa, J.; van der Kuip, D.A.; Hofman, A.; Kors, J.A.; van Herpen, G.; Stricker, B.H.; Stijnen, T.; Lip, G.Y.; Witteman, J.C. Prevalence, incidence and lifetime risk of atrial fibrillation: The rotterdam study. Eur. Heart J., 2006, 27(8), 949-953.
[21]
Wolf, P.A.; Benjamin, E.J.; Belanger, A.J.; Kannel, W.B.; Levy, D.; D’Agostino, R.B. Secular trends in the prevalence of atrial fibrillation: The Framingham Study. Am. Heart J., 1996, 131(4), 790-795.
[22]
Kim, E.J.; Yin, X.; Fontes, J.D.; Magnani, J.W.; Lubitz, S.A.; McManus, D.D.; Seshadri, S.; Vasan, R.S.; Ellinor, P.T.; Larson, M.G.; Benjamin, E.J.; Rienstra, M. Atrial fibrillation without comorbidities: Prevalence, incidence and prognosis (from the Framingham Heart Study). Am. Heart J., 2016, 177, 138-144.
[23]
Jabre, P.; Jouven, X.; Adnet, F.; Thabut, G.; Bielinski, S.J.; Weston, S.A.; Roger, V.L. Atrial fibrillation and death after myocardial infarction: A community study. Circulation, 2011, 123(19), 2094-2100.
[24]
McManus, D.D.; Hsu, G.; Sung, S.H.; Saczynski, J.S.; Smith, D.H.; Magid, D.J.; Gurwitz, J.H.; Goldberg, R.J.; Go, A.S.; Study, C.R.N.P. Atrial fibrillation and outcomes in heart failure with preserved versus reduced left ventricular ejection fraction. J. Am. Heart Assoc., 2013, 2(1), e005694.
[25]
O’Neal, W.T.; Tanner, R.M.; Efird, J.T.; Baber, U.; Alonso, A.; Howard, V.J.; Howard, G.; Muntner, P.; Soliman, E.Z. Atrial fibrillation and incident end-stage renal disease: The REasons for Geographic and Racial Differences in Stroke (REGARDS) study. Int. J. Cardiol., 2015, 185, 219-223.
[26]
Kim, Y.H.; Roh, S.Y. The mechanism of and preventive therapy for stroke in patients with atrial fibrillation. J. Stroke, 2016, 18(2), 129-137.
[27]
Yamamoto, M.; Seo, Y.; Kawamatsu, N.; Sato, K.; Sugano, A.; Machino-Ohtsuka, T.; Kawamura, R.; Nakajima, H.; Igarashi, M.; Sekiguchi, Y.; Ishizu, T.; Aonuma, K. Complex left atrial appendage morphology and left atrial appendage thrombus formation in patients with atrial fibrillation. Circ Cardiovasc Imaging, 2014, 7(2), 337-343.
[28]
Friedman, G.D.; Loveland, D.B.; Ehrlich, S.P., Jr Relationship of stroke to other cardiovascular disease. Circulation, 1968, 38(3), 533-541.
[29]
Fuster, V.; Rydén, L.E.; Cannom, D.S.; Crijns, H.J.; Curtis, A.B.; Ellenbogen, K.A.; Halperin, J.L.; Le Heuzey, J.Y.; Neal Kay, G.; Lowe, J.E.; Bertil Olsson, S.; Prystowsky, E.N.; Tamargo, J.L.; Wann, S. Guidelines for the management of patients with atrial fibrillation. Executive summary. Rev. Esp. Cardiol., 2006, 59(12), 1329.
[30]
Britton, M.; Gustafsson, C. Non-rheumatic atrial fibrillation as a risk factor for stroke. Stroke, 1985, 16(2), 182-188.
[31]
Wolf, P.A.; Kannel, W.B.; McGee, D.L.; Meeks, S.L.; Bharucha, N.E.; McNamara, P.M. Duration of atrial fibrillation and imminence of stroke: The Framingham study. Stroke, 1983, 14(5), 664-667.
[32]
Lin, H.J.; Wolf, P.A.; Kelly-Hayes, M.; Beiser, A.S.; Kase, C.S.; Benjamin, E.J.; D’Agostino, R.B. Stroke severity in atrial fibrillation. The Framingham study. Stroke, 1996, 27(10), 1760-1764.
[33]
Hart, R.G.; Pearce, L.A.; Rothbart, R.M.; McAnulty, J.H.; Asinger, R.W.; Halperin, J.L. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. J. Am. Coll. Cardiol., 2000, 35(1), 183-187.
[34]
Sage, J.I.; Van Uitert, R.L. Risk of recurrent stroke in patients with atrial fibrillation and non-valvular heart disease. Stroke, 1983, 14(4), 537-540.
[35]
Treseder, A.S.; Sastry, B.S.; Thomas, T.P.; Yates, M.A.; Pathy, M.S. Atrial fibrillation and stroke in elderly hospitalized patients. Age Ageing, 1986, 15(2), 89-92.
[36]
Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther., 2001, 69(3), 89-95.
[37]
Becker, R.C. Biomarkers in atrial fibrillation: investigating biologic plausibility, cause, and effect. J. Thromb. Thrombolysis, 2005, 19(1), 71-75.
[38]
Huxley, R.R.; Alonso, A.; Lopez, F.L.; Filion, K.B.; Agarwal, S.K.; Loehr, L.R.; Soliman, E.Z.; Pankow, J.S.; Selvin, E. Type 2 diabetes, glucose homeostasis and incident atrial fibrillation: The atherosclerosis risk in Communities study. Heart, 2012, 98(2), 133-138.
[39]
Wang, T.J.; Parise, H.; Levy, D.; D’Agostino, R.B., Sr; Wolf, P.A.; Vasan, R.S.; Benjamin, E.J. Obesity and the risk of new-onset atrial fibrillation. JAMA, 2004, 292(20), 2471-2477.
[40]
Wanahita, N.; Messerli, F.H.; Bangalore, S.; Gami, A.S.; Somers, V.K.; Steinberg, J.S. Atrial fibrillation and obesity--results of a meta-analysis. Am. Heart J., 2008, 155(2), 310-315.
[41]
Tsang, T.S.; Barnes, M.E.; Miyasaka, Y.; Cha, S.S.; Bailey, K.R.; Verzosa, G.C.; Seward, J.B.; Gersh, B.J. Obesity as a risk factor for the progression of paroxysmal to permanent atrial fibrillation: A longitudinal cohort study of 21 years. Eur. Heart J., 2008, 29(18), 2227-2233.
[42]
Zacharias, A.; Schwann, T.A.; Riordan, C.J.; Durham, S.J.; Shah, A.S.; Habib, R.H. Obesity and risk of new-onset atrial fibrillation after cardiac surgery. Circulation, 2005, 112(21), 3247-3255.
[43]
Abed, H.S.; Samuel, C.S.; Lau, D.H.; Kelly, D.J.; Royce, S.G.; Alasady, M.; Mahajan, R.; Kuklik, P.; Zhang, Y.; Brooks, A.G.; Nelson, A.J.; Worthley, S.G.; Abhayaratna, W.P.; Kalman, J.M.; Wittert, G.A.; Sanders, P. Obesity results in progressive atrial structural and electrical remodeling: Implications for atrial fibrillation. Heart Rhythm, 2013, 10(1), 90-100.
[44]
Thanassoulis, G.; Massaro, J.M.; O’Donnell, C.J.; Hoffmann, U.; Levy, D.; Ellinor, P.T.; Wang, T.J.; Schnabel, R.B.; Vasan, R.S.; Fox, C.S.; Benjamin, E.J. Pericardial fat is associated with prevalent atrial fibrillation: The Framingham heart study. Circ Arrhythm Electrophysiol, 2010, 3(4), 345-350.
[45]
Rabkin, S.W. The relationship between epicardial fat and indices of obesity and the metabolic syndrome: A systematic review and meta-analysis. Metab. Syndr. Relat. Disord., 2014, 12(1), 31-42.
[46]
Hatem, S.N.; Sanders, P. Epicardial adipose tissue and atrial fibrillation. Cardiovasc. Res., 2014, 102(2), 205-213.
[47]
Venteclef, N.; Guglielmi, V.; Balse, E.; Gaborit, B.; Cotillard, A.; Atassi, F.; Amour, J.; Leprince, P.; Dutour, A.; Clément, K.; Hatem, S.N. Human epicardial adipose tissue induces fibrosis of the atrial myocardium through the secretion of adipofibrokines. Eur. Heart J., 2015, 36(13), 795-805a.
[48]
Mahajan, R.; Brooks, A.G.; Shipp, N. Epicardial fat infiltration of atrial musculature creates the substrate for atrial fibrillation in obesity. Heart Rhythm, 2012, 9, S124.
[49]
Aimé-Sempé, C.; Folliguet, T.; Rücker-Martin, C.; Krajewska, M.; Krajewska, S.; Heimburger, M.; Aubier, M.; Mercadier, J.J.; Reed, J.C.; Hatem, S.N. Myocardial cell death in fibrillating and dilated human right atria. J. Am. Coll. Cardiol., 1999, 34(5), 1577-1586.
[50]
Zuk, P.A.; Zhu, M.; Mizuno, H.; Huang, J.; Futrell, J.W.; Katz, A.J.; Benhaim, P.; Lorenz, H.P.; Hedrick, M.H. Multilineage cells from human adipose tissue: Implications for cell-based therapies. Tissue Eng., 2001, 7(2), 211-228.
[51]
Rangappa, S.; Fen, C.; Lee, E.H.; Bongso, A.; Sim, E.K. Transformation of adult mesenchymal stem cells isolated from the fatty tissue into cardiomyocytes. Ann. Thorac. Surg., 2003, 75(3), 775-779.
[52]
Ausma, J.; Wijffels, M.; van Eys, G.; Koide, M.; Ramaekers, F.; Allessie, M.; Borgers, M. Dedifferentiation of atrial cardiomyocytes as a result of chronic atrial fibrillation. Am. J. Pathol., 1997, 151(4), 985-997.
[53]
Gupta, S.; de Lemos, J.A. Use and misuse of cardiac troponins in clinical practice. Prog. Cardiovasc. Dis., 2007, 50(2), 151-165.
[54]
Omland, T.; de Lemos, J.A.; Sabatine, M.S.; Christophi, C.A.; Rice, M.M.; Jablonski, K.A.; Tjora, S.; Domanski, M.J.; Gersh, B.J.; Rouleau, J.L.; Pfeffer, M.A.; Braunwald, E. A sensitive cardiac troponin T assay in stable coronary artery disease. N. Engl. J. Med., 2009, 361(26), 2538-2547.
[55]
Hijazi, Z.; Siegbahn, A.; Andersson, U.; Granger, C.B.; Alexander, J.H.; Atar, D.; Gersh, B.J.; Mohan, P.; Harjola, V.P.; Horowitz, J.; Husted, S.; Hylek, E.M.; Lopes, R.D.; McMurray, J.J.; Wallentin, L.; Investigators, A. High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation, 2014, 129(6), 625-634.
[56]
Wallentin, L.; Hijazi, Z.; Andersson, U.; Alexander, J.H.; De Caterina, R.; Hanna, M.; Horowitz, J.D.; Hylek, E.M.; Lopes, R.D.; Asberg, S.; Granger, C.B.; Siegbahn, A.; Investigators, A. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and other thromboembolic events in Atrial Fibrillation (ARISTOTLE) trial. Circulation, 2014, 130(21), 1847-1858.
[57]
Liu, T.; Li, G.; Li, L.; Korantzopoulos, P. Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a meta-analysis. J. Am. Coll. Cardiol., 2007, 49(15), 1642-1648.
[58]
Levin, E.R.; Gardner, D.G.; Samson, W.K. Natriuretic peptides. N. Engl. J. Med., 1998, 339(5), 321-328.
[59]
Inoue, S.; Murakami, Y.; Sano, K.; Katoh, H.; Shimada, T. Atrium as a source of brain natriuretic polypeptide in patients with atrial fibrillation. J. Card. Fail., 2000, 6(2), 92-96.
[60]
Wozakowska-Kapłon, B. Effect of sinus rhythm restoration on plasma brain natriuretic peptide in patients with atrial fibrillation. Am. J. Cardiol., 2004, 93(12), 1555-1558.
[61]
Wang, Z.; Lu, Y.; Yang, B. MicroRNAs and atrial fibrillation: new fundamentals. Cardiovasc. Res., 2011, 89(4), 710-721.
[62]
Ellinor, P.T.; Lunetta, K.L.; Albert, C.M.; Glazer, N.L.; Ritchie, M.D.; Smith, A.V.; Arking, D.E.; Müller-Nurasyid, M.; Krijthe, B.P.; Lubitz, S.A.; Bis, J.C.; Chung, M.K.; Dörr, M.; Ozaki, K.; Roberts, J.D.; Smith, J.G.; Pfeufer, A.; Sinner, M.F.; Lohman, K.; Ding, J.; Smith, N.L.; Smith, J.D.; Rienstra, M.; Rice, K.M.; Van Wagoner, D.R.; Magnani, J.W.; Wakili, R.; Clauss, S.; Rotter, J.I.; Steinbeck, G.; Launer, L.J.; Davies, R.W.; Borkovich, M.; Harris, T.B.; Lin, H.; Völker, U.; Völzke, H.; Milan, D.J.; Hofman, A.; Boerwinkle, E.; Chen, L.Y.; Soliman, E.Z.; Voight, B.F.; Li, G.; Chakravarti, A.; Kubo, M.; Tedrow, U.B.; Rose, L.M.; Ridker, P.M.; Conen, D.; Tsunoda, T.; Furukawa, T.; Sotoodehnia, N.; Xu, S.; Kamatani, N.; Levy, D.; Nakamura, Y.; Parvez, B.; Mahida, S.; Furie, K.L.; Rosand, J.; Muhammad, R.; Psaty, B.M.; Meitinger, T.; Perz, S.; Wichmann, H.E.; Witteman, J.C.; Kao, W.H.; Kathiresan, S.; Roden, D.M.; Uitterlinden, A.G.; Rivadeneira, F.; McKnight, B.; Sjögren, M.; Newman, A.B.; Liu, Y.; Gollob, M.H.; Melander, O.; Tanaka, T.; Stricker, B.H.; Felix, S.B.; Alonso, A.; Darbar, D.; Barnard, J.; Chasman, D.I.; Heckbert, S.R.; Benjamin, E.J.; Gudnason, V.; Kääb, S. Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat. Genet., 2012, 44(6), 670-675.
[63]
Patton, K.K.; Ellinor, P.T.; Heckbert, S.R.; Christenson, R.H.; DeFilippi, C.; Gottdiener, J.S.; Kronmal, R.A. N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: The cardiovascular health study. Circulation, 2009, 120(18), 1768-1774.
[64]
Fonseca, A.C.; Brito, D.; Pinho e Melo, T.; Geraldes, R.; Canhão, P.; Caplan, L.R.; Ferro, J.M. N-terminal pro-brain natriuretic peptide shows diagnostic accuracy for detecting atrial fibrillation in cryptogenic stroke patients. Int. J. Stroke, 2014, 9(4), 419-425.
[65]
Bergwerff, M.; Gittenberger-de Groot, A.C.; Wisse, L.J.; DeRuiter, M.C.; Wessels, A.; Martin, J.F.; Olson, E.N.; Kern, M.J. Loss of function of the Prx1 and Prx2 homeobox genes alters architecture of the great elastic arteries and ductus arteriosus. Virchows Arch., 2000, 436(1), 12-19.
[66]
Sinner, M.F.; Pfeufer, A.; Akyol, M.; Beckmann, B.M.; Hinterseer, M.; Wacker, A.; Perz, S.; Sauter, W.; Illig, T.; Näbauer, M.; Schmitt, C.; Wichmann, H.E.; Schömig, A.; Steinbeck, G.; Meitinger, T.; Kääb, S. The non-synonymous coding IKr-channel variant KCNH2-K897T is associated with atrial fibrillation: Results from a systematic candidate gene-based analysis of KCNH2 (HERG). Eur. Heart J., 2008, 29(7), 907-914.
[67]
Anderson, J.L.; Allen Maycock, C.A.; Lappé, D.L.; Crandall, B.G.; Horne, B.D.; Bair, T.L.; Morris, S.R.; Li, Q.; Muhlestein, J.B. Frequency of elevation of C-reactive protein in atrial fibrillation. Am. J. Cardiol., 2004, 94(10), 1255-1259.
[68]
Wazni, O.; Martin, D.O.; Marrouche, N.F.; Shaaraoui, M.; Chung, M.K.; Almahameed, S.; Schweikert, R.A.; Saliba, W.I.; Natale, A. C reactive protein concentration and recurrence of atrial fibrillation after electrical cardioversion. Heart, 2005, 91(10), 1303-1305.
[69]
Luan, Y.; Guo, Y.; Li, S.; Yu, B.; Zhu, S.; Li, S.; Li, N.; Tian, Z.; Peng, C.; Cheng, J.; Li, Q.; Cui, J.; Tian, Y. Interleukin-18 among atrial fibrillation patients in the absence of structural heart disease. Europace, 2010, 12(12), 1713-1718.
[70]
Chung, M.K.; Martin, D.O.; Sprecher, D.; Wazni, O.; Kanderian, A.; Carnes, C.A.; Bauer, J.A.; Tchou, P.J.; Niebauer, M.J.; Natale, A.; Van Wagoner, D.R. C-reactive protein elevation in patients with atrial arrhythmias: Inflammatory mechanisms and persistence of atrial fibrillation. Circulation, 2001, 104(24), 2886-2891.
[71]
Leftheriotis, D.I.; Fountoulaki, K.T.; Flevari, P.G.; Parissis, J.T.; Panou, F.K.; Andreadou, I.T.; Venetsanou, K.S.; Iliodromitis, E.K.; Kremastinos, D.T. The predictive value of inflammatory and oxidative markers following the successful cardioversion of persistent lone atrial fibrillation. Int. J. Cardiol., 2009, 135(3), 361-369.
[72]
Roldán, V.; Marín, F.; Martínez, J.G.; García-Herola, A.; Sogorb, F.; Lip, G.Y. Relation of interleukin-6 levels and prothrombin fragment 1+2 to a point-based score for stroke risk in atrial fibrillation. Am. J. Cardiol., 2005, 95(7), 881-882.
[73]
Mihm, M.J.; Yu, F.; Carnes, C.A.; Reiser, P.J.; McCarthy, P.M.; Van Wagoner, D.R.; Bauer, J.A. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation, 2001, 104(2), 174-180.
[74]
Kallergis, E.M.; Manios, E.G.; Kanoupakis, E.M.; Mavrakis, H.E.; Arfanakis, D.A.; Maliaraki, N.E.; Lathourakis, C.E.; Chlouverakis, G.I.; Vardas, P.E. Extracellular matrix alterations in patients with paroxysmal and persistent atrial fibrillation: Biochemical assessment of collagen type-I turnover. J. Am. Coll. Cardiol., 2008, 52(3), 211-215.
[75]
Fu, R.; Wu, S.; Wu, P.; Qiu, J. A study of blood soluble P-selectin, fibrinogen, and von Willebrand factor levels in idiopathic and lone atrial fibrillation. Europace, 2011, 13(1), 31-36.
[76]
Asakura, H.; Hifumi, S.; Jokaji, H.; Saito, M.; Kumabashiri, I.; Uotani, C.; Morishita, E.; Yamazaki, M.; Shibata, K.; Mizuhashi, K. Prothrombin fragment F1 + 2 and thrombin-antithrombin III complex are useful markers of the hypercoagulable state in atrial fibrillation. Blood Coagul. Fibrinolysis, 1992, 3(4), 469-473.
[77]
Zethelius, B.; Johnston, N.; Venge, P. Troponin I as a predictor of coronary heart disease and mortality in 70-year-old men: a community-based cohort study. Circulation, 2006, 113(8), 1071-1078.
[78]
Fox, C.S.; Parise, H.; D’Agostino, R.B., Sr; Lloyd-Jones, D.M.; Vasan, R.S.; Wang, T.J.; Levy, D.; Wolf, P.A.; Benjamin, E.J. Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. JAMA, 2004, 291(23), 2851-2855.
[79]
Arnar, D.O.; Thorvaldsson, S.; Manolio, T.A.; Thorgeirsson, G.; Kristjansson, K.; Hakonarson, H.; Stefansson, K. Familial aggregation of atrial fibrillation in Iceland. Eur. Heart J., 2006, 27(6), 708-712.
[80]
Xu, Y.; Tuteja, D.; Zhang, Z.; Xu, D.; Zhang, Y.; Rodriguez, J.; Nie, L.; Tuxson, H.R.; Young, J.N.; Glatter, K.A.; Vázquez, A.E.; Yamoah, E.N.; Chiamvimonvat, N. Molecular identification and functional roles of a Ca(2+)-activated K+ channel in human and mouse hearts. J. Biol. Chem., 2003, 278(49), 49085-49094.
[81]
Tuteja, D.; Xu, D.; Timofeyev, V.; Lu, L.; Sharma, D.; Zhang, Z.; Xu, Y.; Nie, L.; Vázquez, A.E.; Young, J.N.; Glatter, K.A.; Chiamvimonvat, N. Differential expression of small-conductance Ca2+-activated K+ channels SK1, SK2, and SK3 in mouse atrial and ventricular myocytes. Am. J. Physiol. Heart Circ. Physiol., 2005, 289(6), H2714-H2723.
[82]
Tuteja, D.; Xu, D.; Timofeyev, V.; Lu, L.; Sharma, D.; Zhang, Z.; Xu, Y.; Nie, L.; Vázquez, A.E.; Young, J.N.; Glatter, K.A.; Chiamvimonvat, N. Differential expression of small-conductance Ca2+-activated K+ channels SK1, SK2, and SK3 in mouse atrial and ventricular myocytes. Am. J. Physiol. Heart Circ. Physiol., 2005, 289(6), H2714-H2723.
[83]
Holm, H.; Gudbjartsson, D.F.; Arnar, D.O.; Thorleifsson, G.; Thorgeirsson, G.; Stefansdottir, H.; Gudjonsson, S.A.; Jonasdottir, A.; Mathiesen, E.B.; Njølstad, I.; Nyrnes, A.; Wilsgaard, T.; Hald, E.M.; Hveem, K.; Stoltenberg, C.; Løchen, M.L.; Kong, A.; Thorsteinsdottir, U.; Stefansson, K. Several common variants modulate heart rate, PR interval and QRS duration. Nat. Genet., 2010, 42(2), 117-122.
[84]
Luo, X.; Pan, Z.; Xiao, J.; Zhang, J.; Lu, Y.; Yang, B. Critical role of microRNAs miR-26 and miR-101 in atrial electrical remodeling in experimental atrial fibrillation. Circulation, 2010, 122, A19345.
[85]
Wang, Z.; Lu, Y.; Yang, B. MicroRNAs and atrial fibrillation: new fundamentals. Cardiovasc. Res., 2011, 89(4), 710-721.
[86]
Venugopal, S.K.; Jiang, J.; Kim, T.H.; Li, Y.; Wang, S.S.; Torok, N.J.; Wu, J.; Zern, M.A. Liver fibrosis causes downregulation of miRNA-150 and miRNA-194 in hepatic stellate cells, and their overexpression causes decreased stellate cell activation. Am. J. Physiol. Gastrointest. Liver Physiol., 2010, 298(1), G101-G106.
[87]
Shan, H.; Zhang, Y.; Lu, Y.; Zhang, Y.; Pan, Z.; Cai, B.; Wang, N.; Li, X.; Feng, T.; Hong, Y.; Yang, B. Downregulation of miR-133 and miR-590 contributes to nicotine-induced atrial remodelling in canines. Cardiovasc. Res., 2009, 83(3), 465-472.
[88]
Adam, O.; Löhfelm, B.; Thum, T.; Gupta, S.K.; Puhl, S.L.; Schäfers, H.J.; Böhm, M.; Laufs, U. Role of miR-21 in the pathogenesis of atrial fibrosis. Basic Res. Cardiol., 2012, 107(5), 278.
[89]
Cardin, S.; Guasch, E.; Luo, X.; Naud, P.; Le Quang, K.; Shi, Y.; Tardif, J.C.; Comtois, P.; Nattel, S. Role for MicroRNA-21 in atrial profibrillatory fibrotic remodeling associated with experimental postinfarction heart failure. Circ Arrhythm Electrophysiol, 2012, 5(5), 1027-1035.
[90]
Li, M.; Zhang, J. Circulating MicroRNAs: Potential and emerging biomarkers for diagnosis of cardiovascular and cerebrovascular diseases. BioMed Res. Int., 2015, 2015, 730535.
[91]
Romaine, S.P.R.; Tomaszewski, M.; Condorelli, G.; Samani, N.J. MicroRNAs in cardiovascular disease: An introduction for clinicians. Heart, 2015, 101(12), 921-928.
[92]
Stoicea, N.; Du, A.; Lakis, D.C.; Tipton, C.; Arias-Morales, C.E.; Bergese, S.D. The MiRNA journey from theory to practice as a CNS biomarker. Front. Genet., 2016, 7, 11.
[93]
Faruq, O.; Vecchione, A. microRNA: Diagnostic Perspective. Front. Med. (Lausanne), 2015, 2, 51.
[94]
European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery; Camm A.J.; Kirchhof, P.; Lip, G.Y.; Schotten, U.; Savelieva, I.; Ernst, S.; Van, Gelder, I.C.; Al-Attar, N.; Hindricks, G.; Prendergast, B.; Heidbuchel, H.; Alfieri, O.; Angelini, A.; Atar, D.; Colonna, P.; De Caterina, R.; De Sutter, J.; Goette, A.; Gorenek, B.; Heldal, M.; Hohloser, S.H.; Kolh, P.; Le Heuzey, J.Y.; Ponikowski, P.; Rutten, F.H. Guidelines for the management of atrial fibrillation: The task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur. Heart J., 2010, 19, 2369-2429.
[95]
Lip, G.Y.; Nieuwlaat, R.; Pisters, R.; Lane, D.A.; Crijns, H.J. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest, 2010, 137(2), 263-272.
[96]
Nakamura, Y.; Nakamura, K.; Fukushima-Kusano, K.; Ohta, K.; Matsubara, H.; Hamuro, T.; Yutani, C.; Ohe, T. Tissue factor expression in atrial endothelia associated with nonvalvular atrial fibrillation: possible involvement in intracardiac thrombogenesis. Thromb. Res., 2003, 111(3), 137-142.
[97]
Fukuchi, M.; Watanabe, J.; Kumagai, K.; Katori, Y.; Baba, S.; Fukuda, K.; Yagi, T.; Iguchi, A.; Yokoyama, H.; Miura, M.; Kagaya, Y.; Sato, S.; Tabayashi, K.; Shirato, K. Increased von Willebrand factor in the endocardium as a local predisposing factor for thrombogenesis in overloaded human atrial appendage. J. Am. Coll. Cardiol., 2001, 37(5), 1436-1442.
[98]
Li-Saw-Hee, F.L.; Blann, A.D.; Gurney, D.; Lip, G.Y. Plasma von Willebrand factor, fibrinogen and soluble P-selectin levels in paroxysmal, persistent and permanent atrial fibrillation. Effects of cardioversion and return of left atrial function. Eur. Heart J., 2001, 22(18), 1741-1747.
[99]
Nakajima, K. The relationship between left atrial thrombus and hematological markers in patients with chronic non-rheumatic atrial fibrillation. Nippon Ronen Igakkai Zasshi, 2000, 37(11), 903-907.
[100]
Nakagawa, K.; Hirai, T.; Shinokawa, N.; Uchiyama, Y.; Kameyama, T.; Takashima, S.; Fujiki, A.; Asanoi, H.; Inoue, H. Relation of fibrillatory wave amplitude with hemostatic abnormality and left atrial appendage dysfunction in patients with chronic nonrheumatic atrial fibrillation. Jpn. Circ. J., 2001, 65(5), 375-380.
[101]
Nakajima, K. The relationship between left atrial thrombus and hematological markers in patients with chronic non-rheumatic atrial fibrillation. Nippon Ronen Igakkai Zasshi, 2000, 37(11), 903-907.
[102]
Somlói, M.; Tomcsányi, J.; Nagy, E.; Bodó, I.; Bezzegh, A. D-dimer determination as a screening tool to exclude atrial thrombi in atrial fibrillation. Am. J. Cardiol., 2003, 92(1), 85-87.
[103]
Eikelboom, J.; Hijazi, Z.; Oldgren, J.; Andersson, U.; Connolly, S.J.; Ezekowitz, M.D.; Reilly, P.A.; Yusuf, S.; Wallentin, L.; Siegbahn, A. D-dimer is prognostic for stroke, major bleeding and death during anticoagulation of atrial fibrillation - a RELY substudy. Circulation, 2010, 122, A18321.
[104]
Christersson, C.; Schollin, M.; Alexander, J.H.; Bersh, B.J.; Horowitz, J.; Hylek, E.M.; Mohan, P.; Granger, C.B.; Wallentin, L.; Siegbahn, A. Increased levels of D-dimer in atrial fibrillation identify patients with higher risk of thromboembolic events and death. European Heart Journal (Vol. 33, No. Suppl 1, pp. 969-969).
[105]
Alvarez-Perez, F.J.; Castelo-Branco, M.; Alvarez-Sabin, J. Usefulness of measurement of fibrinogen, D-dimer, D-dimer/fibrinogen ratio, C reactive protein and erythrocyte sedimentation rate to assess the pathophysiology and mechanism of ischaemic stroke. J. Neurol. Neurosurg. Psychiatry, 2011, 82(9), 986-992.
[106]
Freestone, B.; Chong, A.Y.; Nuttall, S.; Blann, A.D.; Lip, G.Y. Soluble E-selectin, von Willebrand factor, soluble thrombomodulin, and total body nitrate/nitrite product as indices of endothelial damage/dysfunction in paroxysmal, persistent, and permanent atrial fibrillation. Chest, 2007, 132(4), 1253-1258.
[107]
Hanson, E.; Jood, K.; Karlsson, S.; Nilsson, S.; Blomstrand, C.; Jern, C. Plasma levels of von Willebrand factor in the etiologic subtypes of ischemic stroke. J. Thromb. Haemost., 2011, 9(2), 275-281.
[108]
Choudhury, A.; Chung, I.; Blann, A.D.; Lip, G.Y. Platelet surface CD62P and CD63, mean platelet volume, and soluble/platelet P-selectin as indexes of platelet function in atrial fibrillation: a comparison of “healthy control subjects” and “disease control subjects” in sinus rhythm. J. Am. Coll. Cardiol., 2007, 49(19), 1957-1964.
[109]
Tsang, T.S.; Gersh, B.J.; Appleton, C.P.; Tajik, A.J.; Barnes, M.E.; Bailey, K.R.; Oh, J.K.; Leibson, C.; Montgomery, S.C.; Seward, J.B. Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J. Am. Coll. Cardiol., 2002, 40(9), 1636-1644.
[110]
Hijazi, Z.; Wallentin, L.; Siegbahn, A.; Andersson, U.; Christersson, C.; Ezekowitz, J.; Gersh, B.J.; Hanna, M.; Hohnloser, S.; Horowitz, J.; Huber, K.; Hylek, E.M.; Lopes, R.D.; McMurray, J.J.; Granger, C.B. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the prevention of stroke in subjects with atrial fibrillation). J. Am. Coll. Cardiol., 2013, 61(22), 2274-2284.
[111]
Shimizu, H.; Murakami, Y.; Inoue, S.; Ohta, Y.; Nakamura, K.; Katoh, H.; Sakne, T.; Takahashi, N.; Ohata, S.; Sugamori, T.; Ishibashi, Y.; Shimada, T. High plasma brain natriuretic polypeptide level as a marker of risk for thromboembolism in patients with nonvalvular atrial fibrillation. Stroke, 2002, 33(4), 1005-1010.
[112]
Yukiiri, K.; Hosomi, N.; Naya, T.; Takahashi, T.; Ohkita, H.; Mukai, M.; Masugata, H.; Murao, K.; Ueno, M.; Nakamura, T.; Dobashi, H.; Miki, T.; Kuroda, Y.; Kohno, M. Plasma brain natriuretic peptide as a surrogate marker for cardioembolic stroke. BMC Neurol., 2008, 8, 45.
[113]
Rodríguez-Yáñez, M.; Sobrino, T.; Blanco, M.; de la Ossa, N.P.; Brea, D.; Rodríguez-González, R.; Leira, R.; Dávalos, A.; Castillo, J. High serum levels of pro-brain natriuretic peptide (pro BNP) identify cardioembolic origin in undetermined stroke. Dis. Markers, 2009, 26(4), 189-195.
[114]
Rost, N.S.; Biffi, A.; Cloonan, L.; Chorba, J.; Kelly, P.; Greer, D.; Ellinor, P.; Furie, K.L. Brain natriuretic peptide predicts functional outcome in ischemic stroke. Stroke, 2012, 43(2), 441-445.
[115]
Hijazi, Z.; Oldgren, J.; Andersson, U.; Connolly, S.J.; Ezekowitz, M.D.; Hohnloser, S.H.; Reilly, P.A.; Vinereanu, D.; Siegbahn, A.; Yusuf, S.; Wallentin, L. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: A randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy. Circulation, 2012, 125(13), 1605-1616.
[116]
Eggers, K.M.; Lind, L.; Ahlström, H.; Bjerner, T.; Ebeling Barbier, C.; Larsson, A.; Venge, P.; Lindahl, B. Prevalence and pathophysiological mechanisms of elevated cardiac troponin I levels in a population-based sample of elderly subjects. Eur. Heart J., 2008, 29(18), 2252-2258.
[117]
Pirat, B.; Atar, I.; Ertan, C.; Bozbas, H.; Gulmez, O.; Müderrisoglu, H.; Ozin, B. Comparison of C-reactive protein levels in patients who do and do not develop atrial fibrillation during electrophysiologic study. Am. J. Cardiol., 2007, 100(10), 1552-1555.
[118]
Hijazi, Z.; Lindbäck, J.; Alexander, J.H.; Hanna, M.; Held, C.; Hylek, E.M.; Lopes, R.D.; Oldgren, J.; Siegbahn, A.; Stewart, R.A.; White, H.D.; Granger, C.B.; Wallentin, L. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. Eur. Heart J., 2016, 37(20), 1582-1590.
[119]
Conway, D.S.; Buggins, P.; Hughes, E.; Lip, G.Y. Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation. J. Am. Coll. Cardiol., 2004, 43(11), 2075-2082.
[120]
Crandall, M.A.; Horne, B.D.; Day, J.D.; Anderson, J.L.; Muhlestein, J.B.; Crandall, B.G.; Weiss, J.P.; Lappé, D.L.; Bunch, T.J. Atrial fibrillation and CHADS2 risk factors are associated with highly sensitive C-reactive protein incrementally and independently. Pacing Clin. Electrophysiol., 2009, 32(5), 648-652.
[121]
Bernhardt, P.; Schmidt, H.; Hammerstingl, C.; Lüderitz, B.; Omran, H. Patients with atrial fibrillation and dense spontaneous echo contrast at high risk a prospective and serial follow-up over 12 months with transesophageal echocardiography and cerebral magnetic resonance imaging. J. Am. Coll. Cardiol., 2005, 45(11), 1807-1812.
[122]
Conway, D.S.; Buggins, P.; Hughes, E.; Lip, G.Y. Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation. Am. Heart J., 2004, 148(3), 462-466.
[123]
Lip, G.Y.; Patel, J.V.; Hughes, E.; Hart, R.G. High-sensitivity C-reactive protein and soluble CD40 ligand as indices of inflammation and platelet activation in 880 patients with nonvalvular atrial fibrillation: Relationship to stroke risk factors, stroke risk stratification schema, and prognosis. Stroke, 2007, 38(4), 1229-1237.
[124]
Hermida, J.; Lopez, F.L.; Montes, R.; Matsushita, K.; Astor, B.C.; Alonso, A. Usefulness of high-sensitivity C-reactive protein to predict mortality in patients with atrial fibrillation (from the Atherosclerosis Risk in Communities [ARIC] Study). Am. J. Cardiol., 2012, 109(1), 95-99.
[125]
Psychari, S.N.; Apostolou, T.S.; Sinos, L.; Hamodraka, E.; Liakos, G.; Kremastinos, D.T. Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation. Am. J. Cardiol., 2005, 95(6), 764-767.
[126]
Goswami, K.C.; Yadav, R.; Rao, M.B.; Bahl, V.K.; Talwar, K.K.; Manchanda, S.C. Clinical and echocardiographic predictors of left atrial clot and spontaneous echo contrast in patients with severe rheumatic mitral stenosis: a prospective study in 200 patients by transesophageal echocardiography. Int. J. Cardiol., 2000, 73(3), 273-279.
[127]
Wollert, K.C.; Kempf, T. GDF-15 in heart failure: Providing insight into end-organ dysfunction and its recovery? Eur. J. Heart Fail., 2012, 14(11), 1191-1193.
[128]
Lind, L.; Wallentin, L.; Kempf, T.; Tapken, H.; Quint, A.; Lindahl, B.; Olofsson, S.; Venge, P.; Larsson, A.; Hulthe, J.; Elmgren, A.; Wollert, K.C. Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: Results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study. Eur. Heart J., 2009, 30(19), 2346-2353.
[129]
Anand, I.S.; Kempf, T.; Rector, T.S.; Tapken, H.; Allhoff, T.; Jantzen, F.; Kuskowski, M.; Cohn, J.N.; Drexler, H.; Wollert, K.C. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the valsartan heart failure trial. Circulation, 2010, 122(14), 1387-1395.
[130]
Zhou, Y.M.; Li, M.J.; Zhou, Y.L.; Ma, L.L.; Yi, X. Growth differentiation factor-15 (GDF-15), novel biomarker for assessing atrial fibrosis in patients with atrial fibrillation and rheumatic heart disease. Int. J. Clin. Exp. Med., 2015, 8(11), 21201-21207.
[131]
Go, A.S.; Chertow, G.M.; Fan, D.; McCulloch, C.E.; Hsu, C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med., 2004, 351(13), 1296-1305.
[132]
Santopinto, J.J.; Fox, K.A.; Goldberg, R.J.; Budaj, A.; Piñero, G.; Avezum, A.; Gulba, D.; Esteban, J.; Gore, J.M.; Johnson, J.; Gurfinkel, E.P. Creatinine clearance and adverse hospital outcomes in patients with acute coronary syndromes: Findings from the global registry of acute coronary events (GRACE). Heart, 2003, 89(9), 1003-1008.
[133]
Iguchi, Y.; Kimura, K.; Kobayashi, K.; Aoki, J.; Terasawa, Y.; Sakai, K.; Uemura, J.; Shibazaki, K. Relation of atrial fibrillation to glomerular filtration rate. Am. J. Cardiol., 2008, 102(8), 1056-1059.
[134]
Schmidt, M.; Rieber, J.; Daccarett, M.; Marschang, H.; Sinha, A.M.; Biggar, P.; Jung, P.; Ketteler, M.; Brachmann, J.; Rittger, H. Relation of recurrence of atrial fibrillation after successful cardioversion to renal function. Am. J. Cardiol., 2010, 105(3), 368-372.
[135]
Berkowitsch, A.; Kuniss, M.; Greiss, H.; Wójcik, M.; Zaltsberg, S.; Lehinant, S.; Erkapic, D.; Pajitnev, D.; Pitschner, H.F.; Hamm, C.W.; Neumann, T. Impact of impaired renal function and metabolic syndrome on the recurrence of atrial fibrillation after catheter ablation: a long term follow-up. Pacing Clin. Electrophysiol., 2012, 35(5), 532-543.
[136]
Go, A.S.; Fang, M.C.; Udaltsova, N.; Chang, Y.; Pomernacki, N.K.; Borowsky, L.; Singer, D.E.; Investigators, A.S. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: The anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation, 2009, 119(10), 1363-1369.
[137]
Hohnloser, S.H.; Hijazi, Z.; Thomas, L.; Alexander, J.H.; Amerena, J.; Hanna, M.; Keltai, M.; Lanas, F.; Lopes, R.D.; Lopez-Sendon, J.; Granger, C.B.; Wallentin, L. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur. Heart J., 2012, 33(22), 2821-2830.
[138]
Newman, D.J.; Thakkar, H.; Edwards, R.G.; Wilkie, M.; White, T.; Grubb, A.O.; Price, C.P. Serum cystatin C measured by automated immunoassay: A more sensitive marker of changes in GFR than serum creatinine. Kidney Int., 1995, 47(1), 312-318.
[139]
Laterza, O.F.; Price, C.P.; Scott, M.G. Cystatin C: an improved estimator of glomerular filtration rate? Clin. Chem., 2002, 48(5), 699-707.
[140]
Imai, A.; Komatsu, S.; Ohara, T.; Kamata, T.; Yoshida, J.; Miyaji, K.; Shimizu, Y.; Takewa, M.; Hirayama, A.; Deshpande, G.A.; Takahashi, O.; Kodama, K. Serum cystatin C is associated with early stage coronary atherosclerotic plaque morphology on multidetector computed tomography. Atherosclerosis, 2011, 218(2), 350-355.
[141]
Hijazi, Z.; Oldgren, J.; Andersson, U.; Connolly, S.J.; Ezekowitz, M.D.; Hohnloser, S.H.; Reilly, P.A.; Siegbahn, A.; Yusuf, S.; Wallentin, L. Cystatin C is prognostic for
stroke, death and bleeding during anticoagulation of atrial
fibrillation - a RELY substudy. Circulation, 2011. AHA 124, A12492.
[142]
Gudbjartsson, D.F.; Arnar, D.O.; Helgadottir, A.; Gretarsdottir, S.; Holm, H.; Sigurdsson, A.; Jonasdottir, A.; Baker, A.; Thorleifsson, G.; Kristjansson, K.; Palsson, A.; Blondal, T.; Sulem, P.; Backman, V.M.; Hardarson, G.A.; Palsdottir, E.; Helgason, A.; Sigurjonsdottir, R.; Sverrisson, J.T.; Kostulas, K.; Ng, M.C.; Baum, L.; So, W.Y.; Wong, K.S.; Chan, J.C.; Furie, K.L.; Greenberg, S.M.; Sale, M.; Kelly, P.; MacRae, C.A.; Smith, E.E.; Rosand, J.; Hillert, J.; Ma, R.C.; Ellinor, P.T.; Thorgeirsson, G.; Gulcher, J.R.; Kong, A.; Thorsteinsdottir, U.; Stefansson, K. Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature, 2007, 448(7151), 353-357.
[143]
Gretarsdottir, S.; Thorleifsson, G.; Manolescu, A.; Styrkarsdottir, U.; Helgadottir, A.; Gschwendtner, A.; Kostulas, K.; Kuhlenbäumer, G.; Bevan, S.; Jonsdottir, T.; Bjarnason, H.; Saemundsdottir, J.; Palsson, S.; Arnar, D.O.; Holm, H.; Thorgeirsson, G.; Valdimarsson, E.M.; Sveinbjörnsdottir, S.; Gieger, C.; Berger, K.; Wichmann, H.E.; Hillert, J.; Markus, H.; Gulcher, J.R.; Ringelstein, E.B.; Kong, A.; Dichgans, M.; Gudbjartsson, D.F.; Thorsteinsdottir, U.; Stefansson, K. Risk variants for atrial fibrillation on chromosome 4q25 associate with ischemic stroke. Ann. Neurol., 2008, 64(4), 402-409.
[144]
Gudbjartsson, D.F.; Holm, H.; Gretarsdottir, S.; Thorleifsson, G.; Walters, G.B.; Thorgeirsson, G.; Gulcher, J.; Mathiesen, E.B.; Njølstad, I.; Nyrnes, A.; Wilsgaard, T.; Hald, E.M.; Hveem, K.; Stoltenberg, C.; Kucera, G.; Stubblefield, T.; Carter, S.; Roden, D.; Ng, M.C.; Baum, L.; So, W.Y.; Wong, K.S.; Chan, J.C.; Gieger, C.; Wichmann, H.E.; Gschwendtner, A.; Dichgans, M.; Kuhlenbäumer, G.; Berger, K.; Ringelstein, E.B.; Bevan, S.; Markus, H.S.; Kostulas, K.; Hillert, J.; Sveinbjörnsdóttir, S.; Valdimarsson, E.M.; Løchen, M.L.; Ma, R.C.; Darbar, D.; Kong, A.; Arnar, D.O.; Thorsteinsdottir, U.; Stefansson, K. A sequence variant in ZFHX3 on 16q22 associates with atrial fibrillation and ischemic stroke. Nat. Genet., 2009, 41(8), 876-878.
[145]
Xu, H.; Tang, Y.; Liu, D.Z.; Ran, R.; Ander, B.P.; Apperson, M.; Liu, X.S.; Khoury, J.C.; Gregg, J.P.; Pancioli, A.; Jauch, E.C.; Wagner, K.R.; Verro, P.; Broderick, J.P.; Sharp, F.R. Gene expression in peripheral blood differs after cardioembolic compared with large-vessel atherosclerotic stroke: biomarkers for the etiology of ischemic stroke. J. Cereb. Blood Flow Metab., 2008, 28(7), 1320-1328.
[146]
Grau, A.J.; Buggle, F.; Becher, H.; Zimmermann, E.; Spiel, M.; Fent, T.; Maiwald, M.; Werle, E.; Zorn, M.; Hengel, H.; Hacke, W. Recent bacterial and viral infection is a risk factor for cerebrovascular ischemia: clinical and biochemical studies. Neurology, 1998, 50(1), 196-203.
[147]
Zeng, L.; Liu, J.; Wang, Y.; Wang, L.; Weng, S.; Tang, Y.; Zheng, C.; Cheng, Q.; Chen, S.; Yang, G.Y. MicroRNA-210 as a novel blood biomarker in acute cerebral ischemia. Front. Biosci. (Elite Ed.), 2011, 3, 1265-1272.
[148]
Gan, C.S.; Wang, C.W.; Tan, K.S. Circulatory microRNA-145 expression is increased in cerebral ischemia. Genet. Mol. Res., 2012, 11(1), 147-152.
[149]
Tan, K.S.; Armugam, A.; Sepramaniam, S.; Lim, K.Y.; Setyowati, K.D.; Wang, C.W.; Jeyaseelan, K. Expression profile of MicroRNAs in young stroke patients. PLoS One, 2009, 4(11), e7689.
[150]
Wazni, O.M.; Tsao, H.M.; Chen, S.A.; Chuang, H.H.; Saliba, W.; Natale, A.; Klein, A.L. Cardiovascular imaging in the management of atrial fibrillation. J. Am. Coll. Cardiol., 2006, 48(10), 2077-2084.
[151]
Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1066 patients from 3 clinical trials. Arch. Intern. Med., 1998, 158(12), 1316-1320.
[152]
Banerjee, A.; Taillandier, S.; Olesen, J.B.; Lane, D.A.; Lallemand, B.; Lip, G.Y.; Fauchier, L. Ejection fraction and outcomes in patients with atrial fibrillation and heart failure: The loire valley atrial fibrillation project. Eur. J. Heart Fail., 2012, 14(3), 295-301.
[153]
Sandhu, R.K.; Hohnloser, S.H.; Pfeffer, M.A.; Yuan, F.; Hart, R.G.; Yusuf, S.; Connolly, S.J.; McAlister, F.A.; Healey, J.S. Relationship between degree of left ventricular dysfunction, symptom status, and risk of embolic events in patients with atrial fibrillation and heart failure. Stroke, 2015, 46(3), 667-672.
[154]
Di Tullio, M.R.; Sacco, R.L.; Sciacca, R.R.; Homma, S. Left atrial size and the risk of ischemic stroke in an ethnically mixed population. Stroke, 1999, 30(10), 2019-2024.
[155]
Leung, D.Y.; Davidson, P.M.; Cranney, G.B.; Walsh, W.F. Thromboembolic risks of left atrial thrombus detected by transesophageal echocardiogram. Am. J. Cardiol., 1997, 79(5), 626-629.
[156]
Tsai, L.M.; Lin, L.J.; Teng, J.K.; Chen, J.H. Prevalence and clinical significance of left atrial thrombus in nonrheumatic atrial fibrillation. Int. J. Cardiol., 1997, 58(2), 163-169.
[157]
Stöllberger, C.; Chnupa, P.; Kronik, G.; Brainin, M.; Finsterer, J.; Schneider, B.; Slany, J. Transesophageal echocardiography to assess embolic risk in patients with atrial fibrillation. ELAT Study Group. Embolism in Left Atrial Thrombi. Ann. Intern. Med., 1998, 128(8), 630-638.
[158]
Zabalgoitia, M.; Halperin, J.L.; Pearce, L.A.; Blackshear, J.L.; Asinger, R.W.; Hart, R.G. Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. J. Am. Coll. Cardiol., 1998, 31(7), 1622-1626.
[159]
Mügge, A.; Kühn, H.; Nikutta, P.; Grote, J.; Lopez, J.A.; Daniel, W.G. Assessment of left atrial appendage function by biplane transesophageal echocardiography in patients with nonrheumatic atrial fibrillation: identification of a subgroup of patients at increased embolic risk. J. Am. Coll. Cardiol., 1994, 23(3), 599-607.
[160]
Inoue, Y.Y.; Alissa, A.; Khurram, I.M.; Fukumoto, K.; Habibi, M.; Venkatesh, B.A.; Zimmerman, S.L.; Nazarian, S.; Berger, R.D.; Calkins, H.; Lima, J.A.; Ashikaga, H. Quantitative tissue-tracking cardiac magnetic resonance (CMR) of left atrial deformation and the risk of stroke in patients with atrial fibrillation. J. Am. Heart Assoc., 2015, 4(4), 4.
[161]
Kong, B.; Liu, Y.; Hu, H.; Wang, L.; Fan, Y.; Mei, Y.; Liu, W.; Liao, J.; Liu, D.; Xing, D.; Huang, H. Left atrial appendage morphology in patients with atrial fibrillation in China: Implications for stroke risk assessment from a single center study. Chin. Med. J. (Engl.), 2014, 127(24), 4210-4214.
[162]
Kimura, T.; Takatsuki, S.; Inagawa, K.; Katsumata, Y.; Nishiyama, T.; Nishiyama, N.; Fukumoto, K.; Aizawa, Y.; Tanimoto, Y.; Tanimoto, K.; Jinzaki, M.; Fukuda, K. Anatomical characteristics of the left atrial appendage in cardiogenic stroke with low CHADS2 scores. Heart Rhythm, 2013, 10(6), 921-925.
[163]
Lupercio, F. Left atrial appendage morphology and stroke risk in patients with atrial fibrillation: a meta-analysis. J. Am. Coll. Cardiol., 2016, 67, 713-713.
[164]
Rodríguez-Yáñez, M.; Sobrino, T.; Blanco, M.; de la Ossa, N.P.; Brea, D.; Rodríguez-González, R.; Leira, R.; Dávalos, A.; Castillo, J. High serum levels of pro-brain natriuretic peptide (pro BNP) identify cardioembolic origin in undetermined stroke. Dis. Markers, 2009, 26(4), 189-195.
[165]
Hijazi, Z.; Aulin, J.; Andersson, U.; Alexander, J.H.; Gersh, B.; Granger, C.B.; Hanna, M.; Horowitz, J.; Hylek, E.M.; Lopes, R.D.; Siegbahn, A.; Wallentin, L.; Investigators, A. Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation. Heart, 2016, 102(7), 171056-171059.
[166]
Hijazi, Z.; Lindbäck, J.; Alexander, J.H.; Hanna, M.; Held, C.; Hylek, E.M.; Lopes, R.D.; Oldgren, J.; Siegbahn, A.; Stewart, R.A.; White, H.D.; Granger, C.B.; Wallentin, L. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. Eur. Heart J., 2016, 37(20), 1582-1590.
[167]
Seppälä, I.; Kleber, M.E.; Bevan, S.; Lyytikäinen, L.P.; Oksala, N.; Hernesniemi, J.A.; Mäkelä, K.M.; Rothwell, P.M.; Sudlow, C.; Dichgans, M.; Mononen, N.; Vlachopoulou, E.; Sinisalo, J.; Delgado, G.E.; Laaksonen, R.; Koskinen, T.; Scharnagl, H.; Kähönen, M.; Markus, H.S.; März, W.; Lehtimäki, T. Associations of functional alanine-glyoxylate aminotransferase 2 gene variants with atrial fibrillation and ischemic stroke. Sci. Rep., 2016, 6, 1056-1059.
[168]
Jickling, G.C.; Stamova, B.; Ander, B.P.; Zhan, X.; Liu, D.; Sison, S.M.; Verro, P.; Sharp, F.R. Prediction of cardioembolic, arterial, and lacunar causes of cryptogenic stroke by gene expression and infarct location. Stroke, 2012, 43(8), 2036-2041.
Download PDF Flyer